Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 9 | 2013 | 348 | 0.850 |
Why?
|
| Daptomycin | 6 | 2013 | 10 | 0.780 |
Why?
|
| Gram-Positive Bacterial Infections | 4 | 2013 | 55 | 0.640 |
Why?
|
| Enterococcus | 4 | 2013 | 55 | 0.490 |
Why?
|
| Pharmacy Service, Hospital | 2 | 2011 | 12 | 0.430 |
Why?
|
| Bacteremia | 2 | 2010 | 96 | 0.390 |
Why?
|
| Vancomycin Resistance | 2 | 2010 | 29 | 0.360 |
Why?
|
| Oxazolidinones | 1 | 2010 | 2 | 0.350 |
Why?
|
| Acetamides | 1 | 2010 | 3 | 0.350 |
Why?
|
| Gout Suppressants | 1 | 2010 | 1 | 0.340 |
Why?
|
| Urate Oxidase | 1 | 2010 | 1 | 0.340 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2010 | 1 | 0.340 |
Why?
|
| Hyperuricemia | 1 | 2010 | 2 | 0.340 |
Why?
|
| Drug Dosage Calculations | 1 | 2010 | 5 | 0.340 |
Why?
|
| Body Weight | 1 | 2010 | 128 | 0.330 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 62 | 0.320 |
Why?
|
| Pharmacists | 3 | 2011 | 15 | 0.250 |
Why?
|
| beta-Lactams | 3 | 2011 | 9 | 0.240 |
Why?
|
| HIV Infections | 1 | 2009 | 452 | 0.230 |
Why?
|
| Staphylococcus aureus | 3 | 2015 | 65 | 0.220 |
Why?
|
| Retrospective Studies | 10 | 2015 | 3185 | 0.190 |
Why?
|
| Staphylococcal Infections | 3 | 2015 | 150 | 0.180 |
Why?
|
| Medication Errors | 2 | 2011 | 10 | 0.180 |
Why?
|
| Antifungal Agents | 2 | 2011 | 38 | 0.170 |
Why?
|
| Treatment Outcome | 7 | 2015 | 3204 | 0.160 |
Why?
|
| Shock, Septic | 2 | 2010 | 59 | 0.160 |
Why?
|
| Humans | 20 | 2015 | 25165 | 0.150 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2008 | 24 | 0.140 |
Why?
|
| Middle Aged | 11 | 2015 | 8303 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 17 | 0.120 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2015 | 20 | 0.120 |
Why?
|
| Anesthetics | 1 | 2015 | 23 | 0.120 |
Why?
|
| Cefazolin | 1 | 2015 | 3 | 0.120 |
Why?
|
| Oxacillin | 1 | 2015 | 2 | 0.120 |
Why?
|
| Methicillin | 1 | 2015 | 5 | 0.120 |
Why?
|
| Child Development | 1 | 2015 | 65 | 0.120 |
Why?
|
| Adult | 9 | 2015 | 7259 | 0.120 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 173 | 0.110 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2011 | 55 | 0.110 |
Why?
|
| Enterococcus faecalis | 1 | 2013 | 5 | 0.110 |
Why?
|
| Endocarditis | 1 | 2013 | 9 | 0.110 |
Why?
|
| Enterococcus faecium | 1 | 2013 | 12 | 0.110 |
Why?
|
| Aged | 9 | 2015 | 8448 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 215 | 0.100 |
Why?
|
| Male | 11 | 2015 | 13815 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2010 | 305 | 0.100 |
Why?
|
| Female | 11 | 2015 | 14161 | 0.100 |
Why?
|
| Medication Reconciliation | 1 | 2011 | 1 | 0.100 |
Why?
|
| Carbapenems | 1 | 2011 | 44 | 0.090 |
Why?
|
| Amphotericin B | 1 | 2011 | 6 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2011 | 5 | 0.090 |
Why?
|
| beta-Lactam Resistance | 2 | 2008 | 14 | 0.090 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2011 | 6 | 0.090 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 12 | 0.090 |
Why?
|
| Methicillin Resistance | 2 | 2008 | 25 | 0.090 |
Why?
|
| Linezolid | 1 | 2010 | 4 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 73 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2013 | 82 | 0.090 |
Why?
|
| Uric Acid | 1 | 2010 | 7 | 0.090 |
Why?
|
| Fluid Therapy | 1 | 2010 | 23 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 18 | 0.090 |
Why?
|
| Drug Costs | 1 | 2010 | 10 | 0.090 |
Why?
|
| Cost Savings | 1 | 2010 | 29 | 0.080 |
Why?
|
| Medication Therapy Management | 1 | 2009 | 4 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2010 | 43 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2010 | 47 | 0.080 |
Why?
|
| Candidiasis | 1 | 2009 | 17 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 114 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2015 | 1772 | 0.080 |
Why?
|
| Time Factors | 5 | 2011 | 1336 | 0.080 |
Why?
|
| Nurses | 1 | 2009 | 39 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 243 | 0.080 |
Why?
|
| Prognosis | 1 | 2010 | 693 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2011 | 4508 | 0.070 |
Why?
|
| Professional Competence | 1 | 2008 | 37 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2007 | 49 | 0.070 |
Why?
|
| Biomarkers | 1 | 2010 | 520 | 0.070 |
Why?
|
| Risk Factors | 2 | 2010 | 2179 | 0.070 |
Why?
|
| Chicago | 1 | 2010 | 916 | 0.070 |
Why?
|
| Critical Care | 1 | 2008 | 112 | 0.070 |
Why?
|
| Endocarditis, Bacterial | 1 | 2006 | 11 | 0.060 |
Why?
|
| Bone Diseases | 1 | 2005 | 21 | 0.060 |
Why?
|
| Joint Diseases | 1 | 2005 | 103 | 0.060 |
Why?
|
| Young Adult | 1 | 2010 | 1813 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 140 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 319 | 0.040 |
Why?
|
| Hospital Mortality | 2 | 2010 | 121 | 0.040 |
Why?
|
| Hospitalization | 2 | 2011 | 284 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2011 | 1618 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 572 | 0.030 |
Why?
|
| Blood | 1 | 2013 | 17 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2013 | 19 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 231 | 0.030 |
Why?
|
| Pseudomonas | 1 | 2011 | 2 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 33 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2011 | 14 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 31 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2011 | 39 | 0.020 |
Why?
|
| Bilirubin | 1 | 2011 | 9 | 0.020 |
Why?
|
| Liposomes | 1 | 2011 | 13 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 40 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 57 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 199 | 0.020 |
Why?
|
| Resuscitation | 1 | 2010 | 10 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2010 | 56 | 0.020 |
Why?
|
| Health Services Research | 1 | 2010 | 34 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 149 | 0.020 |
Why?
|
| Survival Rate | 1 | 2009 | 290 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 712 | 0.020 |
Why?
|
| Inpatients | 1 | 2009 | 113 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 704 | 0.020 |
Why?
|
| Knowledge | 1 | 2008 | 15 | 0.020 |
Why?
|
| Problem Solving | 1 | 2008 | 37 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2010 | 250 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 836 | 0.020 |
Why?
|
| Vancomycin | 1 | 2008 | 50 | 0.020 |
Why?
|
| Cognition | 1 | 2015 | 1270 | 0.020 |
Why?
|
| Cross Infection | 1 | 2010 | 295 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 122 | 0.020 |
Why?
|
| Communication | 1 | 2008 | 101 | 0.020 |
Why?
|
| beta-Lactamases | 1 | 2008 | 95 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 275 | 0.020 |
Why?
|
| Decision Making | 1 | 2008 | 202 | 0.020 |
Why?
|
| United States | 1 | 2011 | 1928 | 0.020 |
Why?
|
| Animals | 1 | 2007 | 3430 | 0.010 |
Why?
|